Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cel-Sci ( (CVM) ) has shared an update.
On May 11, 2026, Cel-Sci announced a strategic partnership, distribution, and revenue-sharing agreement with Amarox covering regulatory affairs, marketing, and potential commercialization of its cancer immunotherapy Multikine for head and neck cancer in Saudi Arabia. The deal may be extended to include the wider Gulf Cooperation Council region, signaling Cel-Sci’s intent to expand its geographic footprint and build a commercial pathway for Multikine in key Middle Eastern markets.
Spark’s Take on CVM Stock
According to Spark, TipRanks’ AI Analyst, CVM is a Neutral.
The score is driven primarily by weak financial performance (pre-revenue losses, ongoing cash burn, and elevated balance sheet/cash flow volatility). Technicals also weigh on the score due to a strong downtrend, partially offset by oversold indicators. Valuation is constrained by negative earnings and the absence of a dividend.
To see Spark’s full report on CVM stock, click here.
More about Cel-Sci
Cel-Sci is a biotechnology company focused on developing immunotherapy treatments for cancer, including its lead product candidate Multikine (Leukocyte Interleukin, Injection) for head and neck cancer. The company targets international markets through partnerships to advance regulatory approvals, marketing, and potential commercialization of its therapies.
Average Trading Volume: 226,160
Technical Sentiment Signal: Sell
Current Market Cap: $10.06M
See more data about CVM stock on TipRanks’ Stock Analysis page.